The EGFR/HER2 signaling pathway is frequently activated in many cancers, including hepatocellular carcinoma, lung cancer, colorectal cancer, and breast cancer, and plays a critical role in carcinogenesis and progression 29-32. The gene discussed is ERBB2; the disease is hepatocellular carcinoma.